Long-term safety of pegloticase in chronic gout refractory to conventional treatment
Open Access
- 10 November 2012
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 72 (9), 1469-1474
- https://doi.org/10.1136/annrheumdis-2012-201795
Abstract
To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout. This open-label extension (OLE) study was conducted at 46 sites in the USA, Canada and Mexico. Patients completing either of two replicate randomised placebo-controlled 6-month trials received pegloticase 8 mg every 2 weeks (biweekly) or every 4 weeks (monthly). Safety was evaluated as the primary outcome, with special interest in gout flares and infusion-related reactions (IRs). Secondary outcomes included urate-lowering and clinical efficacy. Patients (n=149) received a mean±SD of 28±18 pegloticase infusions and were followed for a mean of 25±11 months. Gout flares and IRs were the most frequently reported adverse events; these were least common in patients with a sustained urate-lowering response to treatment and those receiving biweekly treatment. In 10 of the 11 patients with a serious IR, the event occurred when uric acid exceeded 6 mg/dl. Plasma and serum uric acid levels remained <6 mg/dl in most randomised controlled trial (RCT)-defined pegloticase responders throughout the OLE study and were accompanied by sustained and progressive improvements in tophus resolution and flare incidence. The safety profile of long-term pegloticase treatment was consistent with that observed during 6 months of RCT treatment; no new safety signals were identified. Improvements in clinical status, in the form of flare and tophus reduction initiated during RCT pegloticase treatment in patients maintaining goal range urate-lowering responses were sustained or advanced during up to 2.5 years of additional treatment.Keywords
This publication has 18 references indexed in Scilit:
- 2011 Recommendations for the Diagnosis and Management of Gout and HyperuricemiaPostgraduate Medicine, 2011
- Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008Arthritis & Rheumatism, 2011
- Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with GoutThe Journal of Rheumatology, 2009
- Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?Arthritis Care & Research, 2007
- British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of GoutRheumatology, 2007
- Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of goutAnnals Of The Rheumatic Diseases, 2007
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals Of The Rheumatic Diseases, 2006
- A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapyArthritis Care & Research, 2004
- Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Care & Research, 2002
- Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?2001